Progress on Organ Transplants Offers Hope

More than 100,000 Americans are waiting for an organ transplant. Every day, some of them die before an organ becomes available.

The math has been painful for decades: there are not enough donated organs to meet the need.

Now, two fast-moving areas of science are offering new hope. Neither is ready to solve the transplant crisis today, but both are closer than they have ever been.

One approach is called xenotransplantation. That means transplanting organs from animals into humans. The main focus is on pigs, because pig organs are similar in size to human organs. Scientists are genetically editing pigs so their organs may be more compatible with the human body and less likely to be rejected.

The goal is not simply to use animal organs as they are. The goal is to change them enough that a human immune system can accept them, at least with the help of anti-rejection medicine.

According to the information provided, Towana Looney became one of the first patients in a formal clinical trial to receive a gene-edited pig kidney at NYU Langone Health in November 2024. She lived with the organ for 130 days, longer than any previous pig kidney transplant recipient, before an infection forced doctors to reduce her anti-rejection medicine. The kidney was rejected, surgically removed, and she returned to dialysis.

That was a setback. It was also a sign of progress.

For months, a pig kidney functioned inside a human body. That matters. Each trial teaches doctors more about rejection, infection, medication, and which patients may benefit most. Trials are continuing at multiple hospitals, and researchers are watching closely to see whether pig organs can one day become a reliable bridge or alternative for patients who cannot get a human donor organ in time.

The second approach is growing organs in the laboratory from human cells.

This is even more futuristic, but researchers are making progress. Scientists have already grown organoids, which are tiny organ-like structures used to study disease and test treatments. The larger challenge is growing full-size organs with blood vessels, structure, and function strong enough for transplant.

According to the information provided, Stanford researchers reported progress in June 2025 in growing heart and liver organoids with functional blood vessels. That kind of work could help solve one of the biggest problems in lab-grown organs: keeping tissue alive by supplying it with oxygen and nutrients.

A fully transplantable lab-grown human organ is likely still years away. It must be large enough, strong enough, safe enough, and reliable enough to work inside a patient. The science is promising, but the road is long.

Gene-edited pig kidneys may arrive sooner.

Even so, both technologies point toward the same future: a world where organ supply is not limited only by human donation.

That would be a major change for patients with kidney failure, heart failure, liver disease, and other life-threatening conditions. It could reduce long waits, emergency declines, and the heartbreaking reality of people dying while still on the transplant list.

There are serious questions ahead. Scientists must prove these organs are safe. Doctors must manage rejection and infection risks. Regulators must decide when the benefits outweigh the risks. Patients and families must also weigh emotional, religious, and ethical concerns.

But the direction is clear.

For years, transplant medicine has been limited by scarcity. The need was always greater than the supply. Now, researchers are working to change that equation.

Neither pig kidneys nor lab-grown organs will end the transplant shortage tomorrow. But for patients waiting for a second chance, progress itself is powerful.

Hope is no longer just a wish. It is becoming a field of medicine.